Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | HPGDS | O60760 | 8/20 | 0.61 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31460463 | 0.89 | HPGDS (0.64) | MAPTNPC1RAB9AHPGDSMLLT1 | |
| SCHEMBL22939333 | 0.82 | RAB9A (0.74) | MAPTNPC1RAB9AHPGDSKDM4E | |
| SCHEMBL22939439 | 0.82 | MLLT1 (0.61) | MAPTNPC1RAB9AHPGDSMLLT1 | |
| SCHEMBL5342868 | 0.81 | HPGDS (0.61) | NPC1RAB9AHPGDSMLLT1KDM4E | |
| SCHEMBL31460922 | 0.78 | MLLT1 (0.62) | MAPTHPGDSMLLT1MAP4K4 | |
| SCHEMBL5343150 | 0.76 | HPGDS (0.66) | NPC1RAB9AHPGDSMLLT1KDM4E | |
| SCHEMBL25480030 | 0.75 | MLLT1 (0.88) | MAPTNPC1RAB9AHPGDSMLLT1 | |
| SCHEMBL25513463 | 0.74 | MLLT1 (0.87) | MAPTNPC1RAB9AHPGDSMLLT1 | |
| SCHEMBL4490900 | 0.74 | HPGDS (0.58) | HPGDSMLLT1 | |
| SCHEMBL22939414 | 0.73 | MLLT1 (0.73) | MAPTNPC1RAB9AHPGDSMLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274980-A1 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-01 | — | — | US | disclosed |
| WO-2021021904-A1 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021021904-A1 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274980-A1 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | YEATS2, MLLT1, YEATS4 | MAPT 2067/4885NPC1 1451/4885RAB9A 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.